Nomograms May Be Useful for Predicting Survival Survival in Non-metastatic Osteosarcoma
the Cancer Therapy Advisor take:
Age, tumor site, and histologic response were determined to be stronger influences on metastasis-free survival (MFS) and overall survival (OS) for patients with nonmetastatic osteosarcoma compared to sex, tumor size, and pathologic fracture, according to an article published online in the journal Cancer.
A total of 1,070 patients who received neoadjuvant chemotherapy and surgery for nonmetastatic osteosarcoma were studied.
The authors developed multivariate nomograms based on data from Japanese patients (n=557). The nomograms were developed to estimate the probability of MFS and OS 3 and 5 years post-diagnosis using six clinical and pathologic variables.
The nomogram model was validated internally for discrimination and also validated externally using an independent patient sample from Korea (n=513).
Results showed factors with stronger influences on MFS and OS included a patient’s age, tumor location, and histologic response, compared to patient’s sex, tumor size, or pathologic fracture.
The authors concluded that the nomograms predicted the probability of both MFS (concordance index, 0.631) and OS (concordance index, 0.679) well.MFS had a concordance index of 0.682 for external validation, and OS had an index of 0.665.
The study suggests its findings verify the usefulness of nomograms for predicting MFS and OS and for assessing postoperative prognosis.
Age, tumor site, and histologic response determined to be stronger influences on metastasis-free, overall survival for nonmetastatic osteosarcoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer